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OBJECTIVES The aim of this study was to test a possible influence of atorvastatin on the production of
vascular endothelial growth factor (VEGF) in patients with coronary artery disease (CAD)
and in vitro.
BACKGROUND Vascular endothelial growth factor is suggested to be involved in the growth of atherosclerotic
plaque by inducing its neovascularization. Hepatic hydroxymethyl glutaryl-coenzyme A
reductase inhibitors (statins) are known to have atheroprotective effects beyond lipid lowering.
METHODS Blood was collected from 14 male hypercholesterolemic patients with angiographically
confirmed CAD at baseline and after two months of atorvastatin therapy (20 mg/d) and from
eight male control patients. In an ex vivo assay, human coronary artery smooth muscle cells
(HCASMC) were incubated with the patient plasma collected before and after atorvastatin
therapy. To test the direct effect of atorvastatin on VEGF synthesis in vitro, HCASMC were
treated with atorvastatin (1, 3 and 10 M). The VEGF concentration was measured by
enzyme-linked immunosorbent assay.
RESULTS Atorvastatin therapy reduced VEGF plasma levels in CAD patients (from 31.1  6.1 to
19.0  3.6 pg/ml; p  0.05). The VEGF plasma concentration tended to be higher in CAD
patients before treatment compared to control patients (31.1 6.1 vs. 23.4 3.6 pg/ml; p
NS). Plasma collected before therapy induced significantly more VEGF in HCASMC
compared to the plasma collected after treatment and compared to control cells. In vitro,
atorvastatin decreased both the basal and the interleukin-1-induced VEGF release in
HCASMC.
CONCLUSIONS These data suggest that atorvastatin may lower the plasma level of VEGF in CAD patients,
which could represent a novel beneficial effect of this and perhaps other statins. (J Am Coll
Cardiol 2002;39:1951–5) © 2002 by the American College of Cardiology Foundation
Chronic inflammation, a key component of atherogenesis
(1), requires the recruitment of circulating leukocytes into
atherosclerotic plaques. This leukocytic infiltration is prob-
ably enhanced by plaque neovascularization (2,3). With
regard to this potentially harmful effect of neoangiogenesis,
the main angiogenic growth factor, vascular endothelial
growth factor (VEGF), has been investigated in several
studies.
In accordance with the supposed proatherogenic effect of
VEGF, the administration of VEGF to both apo-E/apo-
B100 deficient mice and hypercholesterolemic rabbits en-
hanced plaque growth (4). Additionally, inhibition of an-
giogenesis resulted in the abrogation of plaque formation in
transgenic apo-E knockout mice (5). To our knowledge,
such effects have not been examined so far in human studies
with VEGF protein or gene therapy; however, it is well
documented that VEGF is strongly expressed in human
atherosclerotic vessels, but not in healthy arteries (6).
The clinical benefit of hepatic hydroxymethyl glutaryl-
coenzyme A reductase inhibitors (statins) has been proven
in several large clinical trials (7–10). It is believed that the
reduction in cardiovascular morbidity and mortality is par-
tially due to non–lipid-lowering properties of statins includ-
ing antithrombotic, antiproliferative and anti-inflammatory
effects (11,12). So far, however, there are only a few studies
on the possible influence of statins on VEGF production. It
has been shown that lovastatin decreased VEGF synthesis
in Ha-ras transformed human fibroblasts (13) and that this
antiangiogenic mechanism might be responsible for its
antitumor effect. In addition, mevastatin was demonstrated
to influence VEGF production in rat aortic endothelial cells
(14). Recently, fluvastatin has been shown to lower VEGF
serum levels in patients with hypercholesterolemia or with
hypertension (15).
Regarding the well established benefit of statins and the
potential significance of modulating VEGF levels in pa-
tients with coronary artery disease (CAD), we investigated
the effect of atorvastatin on VEGF plasma concentration in
hypercholesterolemic patients with angiographically con-
firmed CAD. In addition, we examined the effect of
atorvastatin on VEGF production of human coronary artery
smooth muscle cells (HCASMC) in vitro.
METHODS
Patients. Written informed consent was obtained from all
patients. The study complies with the declaration of Hel-
sinki. Ethylenediamine-tetraacetic acid (EDTA) anticoag-
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ulated blood was collected from 14 male patients (age
52.9  2.4 years) with angiographically confirmed CAD
(defined as 30% lumen stenosis in at least one major
coronary artery branch) and with hypercholesterolemia re-
quiring lipid-lowering therapy according to the National
Cholesterol Education Program guidelines (16). Additional
risk factors were hypertension (n  4) and cigarette smok-
ing (n  3) or both (n  3). Smoking status did not change
during the study period. Exclusion criteria included diabetes
mellitus, prior myocardial infarction (1 month before
inclusion), known tumor disease, peripheral arterial occlu-
sive disease, impaired left ventricular function (ejection
fraction 45%) and chronic obstructive pulmonary disease.
Blood was collected before and after a lipid-lowering ther-
apy with atorvastatin (20 mg/d) for two months. Further-
more, EDTA plasma was collected from eight control
patients (age 56.5  1.3 years) who underwent coronary
angiography because of chest pain, which revealed smooth
coronary arteries. Blood was centrifuged for 15 min at 500 g.
Plasma was stored below 30°C.
Reagents. Atorvastatin calcium was a gift from Parke
Davis (Groton, Connecticut). Interleukin (IL)-1 was pur-
chased from Sigma (St. Louis, Missouri); VEGF enzyme-
linked immunosorbent assay (ELISA) kit for determination
of human VEGF was from R&D Systems (Minneapolis,
Minnesota). Lactate dehydrogenase (LDH) release assay
was from Promega (Madison, Wisconsin). Cy-Chrome
anti-human CD3 antibody was purchased from PharMin-
gen (San Diego, California) (Cat. No. 555334) and Lym-
phoprep was obtained from Nycomed (Oslo, Norway).
Cells. Human coronary artery smooth muscle cells were
obtained from Clonetics (CellSystems, St. Katharine, Ger-
many) and cultured till confluence in SmBM with 5% fetal
calf serum (FCS).
Experimental protocols in vitro. Confluent HCASMC
were put on starving medium (0.5% FCS) for 24 h.
Thereafter, cells were treated for 24 h with different
concentrations of atorvastatin (1 to 10 M) diluted in
dimethyl sulfoxide (DMSO) and finally dissolved in the
culture media. The concentration of DMSO never exceeded
0.1% and the control cells were treated with the same
amount of diluent. Some cells were additionally treated with
IL-1 (10 ng/ml). After 24 h, the medium was collected
and used for determination of VEGF concentration and
LDH release. The VEGF levels were determined in at least
three independent experiments performed in duplicate or
triplicate.
Experimental protocols ex vivo. In another set of experi-
ments, HCASMC were treated with 10 l of filter-
sterilized plasma collected from 6 randomly selected pa-
tients of the 14 investigated CAD patients before and after
two months of atorvastatin therapy. Cells were cultured for
24 h and VEGF concentration was determined in the
conditioned media.
VEGF determination. Human VEGF was detected in the
patients’ plasma with Human Quantikine VEGF ELISA.
The VEGF measurements in the samples collected from
CAD patients before and after two months of therapy were
performed at the same time by an investigator blinded to the
kind of treatment applied to the patients. The VEGF
release by HCASMC was determined by the same kit.
Other measurements. Plasma lipid concentrations and
white blood cells were determined by the central laboratory
of the University Clinic of Innsbruck. The LDH release
assay was used to investigate whether atorvastatin exerts any
cytotoxic effect on HCASMC. T-lymphocytes were deter-
mined using FACScan (Becton Dickinson, Belgium) after
incubation of Lymphoprep (Nycomed) separated leukocytes
with 10 l of anti-CD3 antibodies for 30 min at room
temperature.
Statistical analysis. Values are expressed as mean  SEM.
To determine normal distribution of variables, we used the
Kolmogorov-Smirnov test. According to this result,
Wilcoxon-Signed Ranks test and Mann-Whitney U-test
were used for nonparametric comparison. When appropri-
ate, one-way analysis of variance with post hoc Scheffe test
was performed for multiple comparisons. A p value 0.05
was considered to be statistically significant.
RESULTS
The effect of atorvastatin therapy on lipid levels.
Atorvastatin significantly decreased both total cholesterol
and low-density lipoprotein (LDL) cholesterol levels in
CAD patients (Table 1). Total cholesterol level was reduced
by 29.3  2.7% (from 262.3  13.0 to 189.9  8.9 mg/dl;
p  0.001), while LDL cholesterol level decreased by
37.1  4.5% (from 174.4  9.8 to 109.6  9.1 mg/dl; p 
0.001). There was no significant difference in triglycerides
(151.2  16.9 vs. 116.5  8.0 mg/dl; not significant [NS])
and high-density lipoprotein cholesterol levels (59.4  9.7
vs. 49.9  3.0 mg/dl; NS) after treatment with atorvastatin.
The effect of atorvastatin treatment on blood cells. No
significant differences in leukocyte (6,714 360 vs. 6,050
431 cells/l; NS), lymphocyte (1,985  149 vs. 1,889 
151 cells/l; NS), monocyte (566  42 vs. 514  46
cells/l; NS) and thrombocyte counts (234,929  12,558
vs. 216,857  12,832 cells/l; NS) were observed in CAD
patients after atorvastatin treatment (Table 1). Furthermore,
Abbreviations and Acronyms
CAD  coronary artery disease
DMSO  dimethyl sulfoxide
EDTA  ethylenediamine-tetraacetic acid
ELISA  enzyme-linked immunosorbent assay
FCS  fetal calf serum
HCASMC  human coronary artery smooth muscle
cells
IL  interleukin
LDH  lactate dehydrogenase
LDL  low-density lipoprotein
VEGF  vascular endothelial growth factor
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there was no difference in blood cells between control and
CAD patients at any time.
VEGF levels in and ex vivo. In CAD patients, VEGF
plasma concentration was significantly decreased after two
months of atorvastatin therapy (31.1 6.1 pg/ml compared
to 19.0  3.6 pg/ml; p  0.05; Fig. 1). There was a
tendency toward lower VEGF plasma levels in control
patients compared to CAD patients before atorvastatin
treatment (23.4  3.6 vs. 31.1  6.1; p  NS). There was
no significant difference in VEGF plasma concentration
between control subjects and CAD patients after atorvasta-
tin therapy.
When tested ex vivo, plasma collected before therapy
induced significantly more VEGF in HCASMC compared
to the plasma collected after treatment and compared to
control (i.e., nontreated) cells (225.3  27.9% of control
cells vs. 137.0 21.9% of control cells; p 0.03). However,
plasma collected after atorvastatin induced VEGF produc-
tion to a level that is not significantly different from the
basal VEGF generation of nontreated HCASMC (Fig. 2).
VEGF levels in vitro. Atorvastatin (1, 3 and 10 M)
treatment resulted in a significant decrease of VEGF release
in HCASMC compared to untreated control cells (59.0 
10.4%, 58.4  7.3%, 64.9  5.3% of control cells; p 
0.0005; Fig. 3). No inhibition of VEGF synthesis has been
observed with lower concentrations of atorvastatin (data not
shown). In addition, atorvastatin also reversed the IL-1-
induced synthesis of VEGF (Fig. 3).
DISCUSSION
This study demonstrates that atorvastatin leads to a decrease
in the production of VEGF in vitro and in vivo. This is
shown in three ways: 1) VEGF plasma levels of CAD
patients decreased after two months of atorvastatin therapy;
2) plasma collected from patients before atorvastatin treat-
ment increased the VEGF production in HCASMC to a
significantly higher level than the plasma collected after
Table 1. Lipid Levels and Blood Cells in Patients With Coronary Artery Disease and Control
Subjects
Variables Baseline (n  14) Atorvastatin (n  14) Controls (n  8)
Total cholesterol (mg/dl) 262.3  13.0 189.9  8.9† 241.4  11.2‡
LDL cholesterol (mg/dl) 174.4  9.8 109.6  9.1† 170.4  9.7‡
HDL cholesterol (mg/dl) 59.4  9.7 49.9  3.0 53.9  3.2
Triglycerides (mg/dl) 151.2  16.9 116.5  8.0 119.8  22.4
Platelets (l) 234,929  12,558 216,857  12,832 197,500  10,742
Monocytes (l) 566  42 514  46 456  39
Leukocytes (l) 6,714  360 6,050  431 6,688  601
Lymphocytes (l) 1,985  149 1,889  151 1,971  254
Fibrinogen (mg/dl) 375.6  31.3 319.4  16.2 370.4  21.4
VEGF (pg/ml) 31.1  6.1 19.0  3.6* 23.4  3.6
*p  0.05 vs. baseline. †p  0.001 vs. baseline. ‡p  0.01 vs. atorvastatin.
LDL  low-density lipoprotein; HDL  high-density lipoprotein; VEGF  vascular endothelial growth factor.
Figure 1. The effect of atorvastatin therapy on vascular endothelial growth
factor (VEGF) plasma levels. Two months of atorvastatin therapy (20
mg/d) decreased VEGF plasma levels (pg/ml) in patients with coronary
artery disease (CAD) (white bars, *p  0.05). No significant difference in
VEGF plasma concentration between control patients (black bar) and
CAD patients after treatment with atorvastatin could be observed. The
VEGF concentrations in CAD patients tended to be higher compared to
those in control patients (p  NS).
Figure 2. The effect of patient plasma collected before and after therapy
with atorvastatin on vascular endothelial growth factor (VEGF) synthesis
by human coronary artery smooth muscle cells (HCASMC). The VEGF
synthesis in HCASMC (in % of untreated cells, black bar) incubated with
the plasma of patients with coronary artery disease (white bars) collected
before atorvastatin therapy was increased (*p  0.003 vs. untreated cells).
The plasma collected after atorvastatin treatment reversed this stimulatory
effect (#p  0.03 vs. the plasma collected before therapy).
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therapy; and 3) atorvastatin decreased VEGF synthesis in
HCASMC in vitro.
Vascular endothelial growth factor is considered the most
potent angiogenic growth factor for the stimulation of
collateral vessel growth in peripheral (17) and myocardial
(18) ischemia. However, there is accumulating evidence that
VEGF is strongly expressed in atherosclerotic vessels (6,19)
and can enhance neoangiogenesis in atherosclerotic plaque
(4). Celletti et al. (4) have shown that injection of recom-
binant VEGF enhanced atherosclerosis in apo-E/B100
knockout mice and in hypercholesterolemic rabbits, thereby
supporting the possible role of VEGF in plaque progression.
In addition, inhibition of endothelial cell proliferation by
endostatin and TNP-470 in apo-E knockout mice was
shown to attenuate lesion formation (5). Taken together,
these animal studies strongly suggest that VEGF may
aggravate plaque growth. Although adverse events attribut-
able to plaque progression or destabilization in VEGF-
treated patients have not been reported in clinical trials so
far (to our knowledge), the potential proatherogenic effect
of VEGF cannot be fully excluded. While the clinical
settings in which VEGF may be harmful are not evident, a
prudent approach would be to avoid VEGF gene therapy in
stages that are indicative of progressive rather than stable
disease.
If one extrapolates the putative proatherogenic effect of
VEGF to human atherosclerosis, the reduction of VEGF by
atorvastatin could represent another atheroprotective prop-
erty of this statin (12).
In accordance with out data, Blann et al. (20) recently
demonstrated that lipid-lowering therapy with fluvastatin or
fenofibrate decreased the VEGF plasma levels in hypercho-
lesterolemic patients with/without peripheral or carotid
atherosclerosis. Our data extend these observations to pa-
tients with CAD and give additional insight into the
possible mechanisms of statins on VEGF production. In
contrast, Vasa et al. (21) have shown that atorvastatin
therapy (40 mg) for four weeks did not change VEGF levels
in the serum of patients with stable CAD. Potential
explanations for the latter study compared to ours and the
study by Blann et al. (20) partially include methodologic
differences. First, distinct statins (fluvastatin vs. atorvasta-
tin) and different concentrations of statins (40 mg vs. 20 mg
of atorvastatin) were used. Second, the duration of treat-
ment is different. After four weeks of statin therapy, no
effect on VEGF levels was observed by Vasa et al. (21).
However, 8 weeks (our data) and 12 weeks (20) of statin
treatment resulted in decreased VEGF concentrations.
Third, the VEGF concentration was determined in different
kinds of blood samples (serum by Vasa et al. [21] vs. plasma
in ours and in Blann et al. [20]). The fact that the VEGF
plasma levels in the control patients tended to be lower than
in the CAD patients before treatment is in accordance with
a study by Fleisch et al. (22) that showed a trend toward
higher VEGF levels in patients with more advanced CAD.
The lack of statistical significance is probably due to the
small number of control patients.
The influence of atorvastatin on VEGF production can
be attributed to both a direct or indirect effect of statins.
Recently, we have demonstrated that oxidized LDL en-
hanced VEGF expression and generation in vascular
smooth muscle cells (23). Therefore, hypercholesterolemia
may induce VEGF production in different cells including
smooth muscle cells (23), macrophages (24) or endothelial
cells (25). Statin treatment, by decreasing cholesterol level,
probably interferes with a lipid-dependent enhancement of
VEGF. In our ex vivo experiments (Fig. 2), we cannot
exclude that the decreased production of VEGF in
HCASMC is only an epiphenomenon of the lowered
cholesterol content in the plasma of treated CAD patients.
As the total LDL cholesterol amounts in the plasma
collected before and after therapy are only slightly different
and as oxidized LDL is known to stimulate VEGF synthe-
sis (23), the observed reduction of VEGF may be due to an
antioxidative effect of atorvastatin on LDL cholesterol (26).
Statins are known to exert effects independent of their
lipid-lowering activity. This can be related to anti-
inflammatory properties, as evidenced by an inhibition of
the activity of transcription factors (27) and the synthesis of
inflammatory cytokines (28). Our results demonstrate that
atorvastatin reduces both constitutive and cytokine-induced
VEGF synthesis in cell culture (29), a setting in which
cholesterol content is constant (Fig. 3). Therefore, we can
assume that this effect of atorvastatin also represents a
non–lipid-dependent activity.
The clinical significance of the observed decrease in
VEGF plasma levels in CAD patients certainly cannot be
derived from in vitro data. Because we cannot elucidate the
source of the measured VEGF plasma concentration, we
Figure 3. The effect of atorvastatin on vascular endothelial growth factor
(VEGF) synthesis by human coronary artery smooth muscle cells
(HCASMC) in vitro. The VEGF synthesis in HCASMC (in % of
untreated cells). Atorvastatin (1, 3 and 10 mol/l) decreased basal (*p 
0.003 vs. untreated cells) VEGF production in HCASMC. Interleukin
(IL)-1 (10 ng/ml) induced VEGF synthesis (§p  0.003 vs. untreated
cells) in these cells. Incubation of IL-1-treated HCASMC with atorva-
statin again decreased the VEGF production (#p  0.0001 vs. IL-1-
treated cells).
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tried to exclude possible confounding factors. First, we used
EDTA plasma instead of serum. It has been shown previ-
ously that during clotting of blood in a serum tube, VEGF
is released by platelets (30). Second, we determined the
number of monocytes and T-lymphocytes, which are known
sources of VEGF (31,32), and found no difference before
and after therapy with atorvastatin. Third, we excluded all
patients with acute inflammatory diseases, diabetes mellitus
(33), cancer or other chronic diseases in which VEGF is
thought to play a role (34).
In conclusion, we show a decrease in VEGF plasma levels in
CAD patients after two months of atorvastatin therapy. The
results could be confirmed in two different in vitro experiments.
In accordance with the proposed detrimental role of VEGF-
induced neovascularization in atherosclerotic plaque growth,
these observations are likely to represent another beneficial
effect of atorvastatin and perhaps other statins (35).
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